Pancreatic cancer kills more Americans than breast cancer and has a five-year survival rate of just 10 percent. The disease is the third leading cause of cancer-related death in the United States. We are fighting five key challenges:
Not enough researchers and resources in the field
Clinical trials don't match patient needs
Clinical trial enrollment is too low
Many doctors lack experience treating the disease
Lack of public awareness about the disease
PurpleStride fundraising helps us meet these challenges head on.
The Pancreatic Cancer Action Network was founded by Pamela Acosta Marquardt, Paula Kim and Terry Lierman.
Inaugural One Voice Against Cancer advocacy days held in Washington, D.C.
40 volunteer affiliates established nationwide who raised nearly $364,000
Government Affairs & Advocacy office opens in Washington, D.C., and first international affiliate launches in Japan
25,000 patients and caregivers have been served by our call center
Established the Deadliest Cancers Coalition focused on addressing policy issues related to cancers that have five-year relative survival rates below 50 percent
Since 2003, we funded 66 research grants, representing a cumulative investment of approximately $10 million
Recalcitrant Cancer Research Act signed into law requiring the National Cancer Institute to develop a strategic plan on how to fight pancreatic cancer
Nearly 82,000 people participated in our PurpleStride run/walk events that raised $10.5 million
Launched Know Your Tumor® precision medicine service that uses molecular profiling to provide patients and their doctors with information about the biology of their tumor
Launched Clinical Trial Finder online tool with access to the most comprehensive and up-to-date database of pancreatic cancer clinical trials in the U.S.
Led the creation of the World Pancreatic Cancer Coalition representing 40 pancreatic cancer advocacy groups from around the globe
Launched Patient Registry, a global online database created to look for patterns in treatments, side effect management and diagnostics that will lead to improved treatment options and outcomes for patients